Wolfgang Janni, MD, PhD, of the University of Ulm, Ulm, Germany, talks about his side of the debate of whether denosumab or bisphosphonate are more effective drugs for the treatment of breast cancer at the 2016 World Congress on Controversies in Breast Cancer (CoBrCa) in Barcelona, Spain. He explains that his role in the debate is to argue in favor of using denosumab instead of bisphosphonate. He believes that there is very convincing data comparing bisphosphonates and denosumab. Furthermore, the efficacy of denosumab in terms of preventing skeletal-related events, such as pain and also costs associated with with skeletal-related events is much better. He explains that although bisphosphonates have been a lot of help in the past, denosumab is the more effective treatment option now.

свернуть